LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

48.29 0.73

Overview

Share price change

24h

Current

Min

46.46

Max

49

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+8.13% upside

Dividends

By Dow Jones

Next Earnings

4 maj 2026

Market Stats

By TradingEconomics

Market Cap

409M

3B

Previous open

47.56

Previous close

48.29

News Sentiment

By Acuity

50%

50%

161 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lut 2026, 23:07 UTC

Earnings

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 23:01 UTC

Earnings

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:59 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 lut 2026, 22:42 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 lut 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 lut 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 lut 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 lut 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 lut 2026, 23:16 UTC

Earnings

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 lut 2026, 23:13 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 lut 2026, 23:12 UTC

Earnings

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 lut 2026, 23:08 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 lut 2026, 23:07 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 lut 2026, 22:52 UTC

Earnings

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 22:46 UTC

Earnings

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 lut 2026, 22:29 UTC

Earnings

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 lut 2026, 22:28 UTC

Earnings

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 lut 2026, 22:25 UTC

Earnings

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 lut 2026, 22:24 UTC

Earnings

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 lut 2026, 22:23 UTC

Earnings

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 lut 2026, 22:22 UTC

Earnings

Woolworths Interim Dividend 45 Australian Cents/Share

24 lut 2026, 22:22 UTC

Earnings

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 lut 2026, 22:21 UTC

Earnings

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

8.13% upside

12 Months Forecast

Average 52 USD  8.13%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

161 / 351 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat